Insights from Industry RSS Feed - Insights from Industry

'Insights from Industry', a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.
Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’ [More]
Genomics testing in action: an interview with Kevin Haar, CEO, Appistry

Genomics testing in action: an interview with Kevin Haar, CEO, Appistry

The more connections are made between genes, disease and drugs, and the more that we continue to understand about those connections, the more critical genetic testing will become in modern medicine. [More]
Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients. [More]
Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Lysosomes are subcellular organelles that are present in most cells, with the major exception of red blood cells. [More]
Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract. [More]
NMR spectroscopy for in-vitro diagnostic research: an interview with Dr. Manfred Spraul, Director of NMR Applications, Bruker BioSpin

NMR spectroscopy for in-vitro diagnostic research: an interview with Dr. Manfred Spraul, Director of NMR Applications, Bruker BioSpin

Our aim is to open new fields to NMR where we haven’t been before. Because of the extreme stability of our instruments, we can now really think about new applications: going to hospitals, going to food companies and just placing an instrument there that works completely under automation. [More]
Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine! [More]
Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

The last 20 years have been defined by progress and innovation in the multiple sclerosis (MS) field, with now 10 approved treatment options available for people living with relapsing MS, the most common form of the disease. [More]
Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

We start with birth and we collect the cells after C-section. The reason for that is we have to have the mother sign a consent letter that she is donating the placenta and, on top of that, we have to have a blood sample from the mother to test for any viral contamination. [More]
Tissue-engineered medical devices: an interview with Anna Wynn, Business Development Manager, Instron

Tissue-engineered medical devices: an interview with Anna Wynn, Business Development Manager, Instron

Tissue Engineering and Regenerative Medicine (TERM) are dedicated to creating new tissue-engineered medical devices that replace and/or enhance tissue function that has been impaired by disease, injury, or age. [More]
Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children. [More]
Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect. [More]
Telemedicine in action: an interview with Ian Jackson, Managing Director, Imerja

Telemedicine in action: an interview with Ian Jackson, Managing Director, Imerja

Telemedicine is a term used to describe the use of information technology in delivering curative or clinical care healthcare, allowing medical specialists to communicate with patients and other medical staff, regardless of their physical location. [More]
The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines. [More]
DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes. [More]
Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain. [More]
Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet. [More]
Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

We were extremely excited to launch the Impact 2020 report at our annual meeting. Our five-year strategic plan is focused on value, early-stage financing and ensuring more patient-centered discussions. [More]
Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye. [More]

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

MDR-TB is on the rise in a number of regions in the world, because progress towards targets for diagnosis and treatment of multidrug-resistant TB (MDR-TB) is far off-track. [More]